These stocks are bargains.
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
MacroGenics shares jumped in response to another major clinical update today.
Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
Is Tilray's strong first-quarter report a good reason to buy this flagging pot stock?
These three diabetes stocks should be on your radar right now.
An alleged price-fixing scheme is the weighing on the drugmaker's shares today.
Catalyst posted outstanding first-quarter numbers this morning, but the good times may not last.
Sales of the company's Senhance robotic surgery system took a discouraging dip in the first quarter.
Investors are growing impatient with this clinical-stage biotech.
Heplisav-B's commercial launch is starting to ramp up.
Investors were none too pleased with Amneal's first-quarter performance. Here's why.
Intercept's shares continued to slide last month. Here's why.
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.
CRISPR and partner Vertex bagged an important regulatory designation for CTX001 last month.
Novavax's proposed reverse split has investors on edge.
Catalyst's shares are in free fall today after the FDA's surprise approval of a rival LEMS medication.
Heron's falling share price last month turned out to be a bad omen.
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.